Evaluation of Clinical Perfectionism in Parkinson Disease
NCT ID: NCT02824367
Last Updated: 2018-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
60 participants
INTERVENTIONAL
2014-10-06
2018-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Behaviour in Parkinson's Disease. Normal Values in Healthy Subjects
NCT02820428
Coping With Depression in Parkinson's Disease
NCT00464464
Training of Nursing Home Professionals and Quality of Life of Residents With Parkinson's Disease
NCT06908460
Psychiatric and Cognitive Manifestations of Parkinson's Disease
NCT00360633
Online Cognitive Behavioral Therapy for Depressive Symptoms in Parkinson's Disease
NCT05585827
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
To date, few studies used Cognitive Behavioural Therapies (CBT) in people with Parkinson's disease showing promising results. Recently, perfectionism has received particular attention because of it association with many emotional disorders. Thus, some psychometric tools have been developed in order to evaluate different aspects of perfectionism. Yet, none of them has been used in people with Parkinson's disease.
The objective of this study is to investigate whether there is a direct link between Parkinson's disease and perfectionism by using psychometric tools from the CBT literature. Identifying such link would allow to justify the use of CBT in people with Parkinson's disease with the goal in mind to improve their care and quality of life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Parkinsonian
Patient Arm: Parkinsonian will complete several scale of evaluation. Behavioral: Completion of scales evaluation
Completion of scales evaluation
Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
Dystonic
Comparator Arm: Dystonic patient will complete several scale of evaluation. Behavioral: Completion of scales evaluation
Completion of scales evaluation
Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Completion of scales evaluation
Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Score Mini Mental Scale (MMS) greater than 23
* For Parkinsonian, Parkinson disease be defined according to the criteria of the Unified Parkinson Disease Rating Scale (UPDRS), with a Hoehn and Yahr stage 1, 2 or 3
* The control patients present dystonias not within the scope of Parkinson
* Informed Consent Form signed
* Patient covered by social insurance
Exclusion Criteria
* Patients with deep brain stimulation
* Diagnosis of somatic pathology diagnosed
* Private Patient freedom or protected adult (under guardianship)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire, Amiens
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pierre KRYSTKOWIAK, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
CHU Amiens
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU Amiens
Amiens, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-A01302-43
Identifier Type: OTHER
Identifier Source: secondary_id
PI2014_843_0002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.